---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-032353"
form_type: "8-K/A"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T19:04:24.363897+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech amends Q3 2022 8-K to correct CellerateRX facility count from 1,593 to 1,714

## Summary
- Original filing reported CellerateRX approved in 1,593 facilities as of Sep 30, 2022.
- Acquisition of Scendia Biologics added 121 facilities, bringing corrected total to 1,714.
- Amendment only revises this specific number; all other disclosures remain unchanged.
- No change to financial results or any other operational metrics.

## SEC filing metadata
- accession: 0001493152-22-032353
- form_type: 8-K/A
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315222032353/0001493152-22-032353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315222032353/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-032353
- JSON: https://secwatch.observer/filing/0001493152-22-032353.json
- Plain text: https://secwatch.observer/filing/0001493152-22-032353.txt

## Key facts
- Earnings Releases
  Sanara MedTech Inc. reported financial results for quarter ended September 30, 2022.
  - Period: quarter ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, the Company furnished (i) a press release announcing its financial results for the quarter ended September 30, 2022 (the “Press Release”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315222032353/0001493152-22-032353-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.